Schizophrenia Drugs

Mar 02, 2026

Summary The U.S. FDA approved Vanda Pharmaceuticals’ BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone). Vanda’s stock surged nearly 40% after BYSANTI’s approval,...

Oct 14, 2025

After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s USD 14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received FDA approval on 26 September 2024 for the treatm...

Jan 21, 2025

FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer Amgen has secured FDA approval for LUMAKRAS (sotorasib) in combination with VECTIBIX (panitumumab) as a treatment for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxalip...